Rossana Notaristefano

Dr. Rossana Notaristefano

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Thea MagroneThea Magrone
Thea Magrone
MMManrico Magrone
Manrico Magrone
RNRossana Notaristefano
Rossana Notaristefano
EGElona Gaxhja
Elona Gaxhja
NRNajmeh Rezaeinezhad
Najmeh Rezaeinezhad
MCMarica Colella
Marica Colella
The number of food allergies (FAs) is growing, particularly in industrialized countries, resulting in discomfort and a reduction in the quality of life of those who suffer from these allergies. Despite numerous epidemiological studies on FAs worldwide, the different approaches used constitute a limitation for an accurate prevalence of these disorders. The onset of FAs is multifactorial, since it depends on lifestyle, habitat, diet, and particularly on the diversity of gut microbiota. In fact, they occur in conditions of gut dysbiosis, an increase of the inflammatory state, an alteration of gut permeability, and an impairment of the resident immune cells, thus leading to a disruption and/or lack of tolerance towards food allergens. It is important to emphasize that the reduction of some bacteria leads to a decrease in their metabolite production, which, in turn, is crucial for the correct performance of immune responses and to ensure tolerance against allergens. Therefore, various strategies such as pre- and probiotic administration must be employed to avoid or prevent the onset of FAs.

4 September 2026 in Livers
Verified
Journal Article
Open access
PDF file
MCMarica Colella
Marica Colella
RNRossana Notaristefano
Rossana Notaristefano
MTMaria Tragni
Maria Tragni
MMManuela Mandorino
Manuela Mandorino
Background: Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by the metabolic dysfunction-associated steatotic liver disease (MASLD) framework, is a leading cause of chronic liver disease worldwide and is closely linked to obesity, insulin resistance, type 2 diabetes (T2D), and cardiometabolic dysfunction. Although hepatic lipid accumulation and metabolic injury remain central to its pathogenesis, increasing evidence implicates the intestinal microbiota as a modulator of disease onset and progression through the gut–liver axis. Objectives: This narrative review summarizes current evidence linking gut microbiota to NAFLD/MASLD, with emphasis on functional microbial alterations relevant to the gut–liver axis, disease severity, microbiota-related biomarkers, and microbiota-targeted interventions. Methods: The literature search for this narrative review was mainly performed using PubMed/MEDLINE (which produced 200 results since 2023). The search addressed the relationship between gut microbiota, NAFLD/MASLD, and gut–liver axis dysfunction. Results: Early studies mainly focused on disease-associated bacterial taxa; however, no consistent microbial signature has been reproduced across populations, disease stages, and methodological platforms. This limitation supports a shift from a taxonomic view of dysbiosis toward a functional interpretation. Different microbial communities may converge on shared pathogenic outputs, including impaired epithelial barrier integrity, microbial translocation, lipopolysaccharide-driven Toll-like receptor 4 activation, bile acid remodelling, altered short-chain fatty acid production, endogenous ethanol generation, choline and trimethylamine-N-oxide metabolism, and tryptophan-derived indole signalling. These mechanisms may influence hepatic steatosis, inflammatory activation, and fibrogenesis. Conclusions: Current data support the microbiota as a biologically plausible disease modifier, but not yet as a standalone diagnostic or therapeutic target; clinical translation will require longitudinal, multi-omics, and function-oriented studies.